The purpose of this study is to investigate the time course of PF-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
42
PF-00241939 300 ug using inhaler A
PF-00241939 300 ug using inhaler A
PF-00241939 300 ug using inhaler A
Pfizer Investigational Site
Singapore, Singapore
Plasma pharmacokinetic parameters: AUClast and Cmax.
Time frame: 36 hours
Plasma pharmacokinetic parameters: AUC24, AUCinf, Tmax and half-life.
Time frame: 36 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
PF-00241939 300 ug using inhaler B
PF-00241939 300 ug using inhaler B
PF-00241939 300 ug using inhaler B
PF-00241939 300 ug using inhaler B